Allergan’s Oral CGRP Inhibitor Ubrelvy Approved For Migraine Attacks

 
• By Mandy Jackson
FDA Approved
The US FDA approved Allergan's oral CGRP inhibitor Ubrelvy on 23 December.

More from New Products

More from Scrip